CN105705150B - 用于癌症治疗的包含短链脂肪酸和折布拉林或1′-氰基-阿糖胞苷的互联体前药 - Google Patents
用于癌症治疗的包含短链脂肪酸和折布拉林或1′-氰基-阿糖胞苷的互联体前药 Download PDFInfo
- Publication number
- CN105705150B CN105705150B CN201480060553.4A CN201480060553A CN105705150B CN 105705150 B CN105705150 B CN 105705150B CN 201480060553 A CN201480060553 A CN 201480060553A CN 105705150 B CN105705150 B CN 105705150B
- Authority
- CN
- China
- Prior art keywords
- compound
- mutual prodrug
- cancer
- prodrug compound
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
化合物 | 相对反应速度 |
胞苷 | 1 |
Ara-C | 0.4 |
化合物11 | <0.01 |
样本 | 给药途径 | 给药方案 | %TGI | %BW变化 |
溶媒组 | IP | 5d ON/2d Off×2 | 0 | +11.5 |
Ara-C | 40mpk,IP | 5d ON/2d Off×2 | 46 | -6.2 |
化合物12 | 60mpk,PO | 5d ON/2d Off×2 | 50 | -0.9 |
溶媒 | 化合物12 | 化合物12 | 化合物12 | Ara-C | |
剂量 | - | 20mpk | 40mpk | 60mpk | 60mpk |
TGI(%) | - | 36 | 46 | 59 | 60 |
Claims (10)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361904064P | 2013-11-14 | 2013-11-14 | |
US61/904,064 | 2013-11-14 | ||
PCT/KR2014/010972 WO2015072784A1 (en) | 2013-11-14 | 2014-11-14 | Mutual prodrug comprising short chain fatty acids and zebularine or 1'-cyano-cytarabine for cancer treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105705150A CN105705150A (zh) | 2016-06-22 |
CN105705150B true CN105705150B (zh) | 2021-03-23 |
Family
ID=53057653
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201480060553.4A Active CN105705150B (zh) | 2013-11-14 | 2014-11-14 | 用于癌症治疗的包含短链脂肪酸和折布拉林或1′-氰基-阿糖胞苷的互联体前药 |
Country Status (14)
Country | Link |
---|---|
US (1) | US10500224B2 (zh) |
EP (1) | EP3068406B1 (zh) |
JP (1) | JP6215484B2 (zh) |
KR (1) | KR101869940B1 (zh) |
CN (1) | CN105705150B (zh) |
AU (1) | AU2014349328A1 (zh) |
BR (1) | BR112016008934B1 (zh) |
CA (1) | CA2926909A1 (zh) |
DK (1) | DK3068406T3 (zh) |
ES (1) | ES2778524T3 (zh) |
HU (1) | HUE048844T2 (zh) |
MX (1) | MX2016005900A (zh) |
PL (1) | PL3068406T3 (zh) |
WO (1) | WO2015072784A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016195353A1 (en) * | 2015-06-01 | 2016-12-08 | Kainos Medicine, Inc. | A use of 1'-cyano-cytarabine for cancer treatment |
WO2017158396A1 (en) * | 2016-03-16 | 2017-09-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Cytidine deaminase inhibitors for the treatment of pancreatic cancer |
RU2748103C1 (ru) * | 2019-12-13 | 2021-05-19 | Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) | Средство для ингибирования фермента тирозил-ДНК-фосфодиэстеразы 1 человека на основе производных пентафуранозилнуклеозидов |
CN113387954B (zh) * | 2020-03-11 | 2024-03-19 | 上海特化医药科技有限公司 | 一种瑞德西韦中间体的制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130196941A1 (en) * | 2010-07-13 | 2013-08-01 | Clavis Pharma Asa | Parenteral formulations of elacytarabine derivatives |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1297398A (zh) * | 1969-08-06 | 1972-11-22 | ||
US5736531A (en) * | 1987-10-28 | 1998-04-07 | Pro-Neuron, Inc. | Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides |
JPH07109289A (ja) | 1993-08-18 | 1995-04-25 | Yamasa Shoyu Co Ltd | 1’位炭素置換ピリミジンヌクレオシドおよびその製造法 |
AU2002322805B2 (en) | 2001-07-31 | 2007-11-08 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Inhibitor of DNA methylation |
-
2014
- 2014-11-14 DK DK14862419.0T patent/DK3068406T3/da active
- 2014-11-14 BR BR112016008934-0A patent/BR112016008934B1/pt active IP Right Grant
- 2014-11-14 HU HUE14862419A patent/HUE048844T2/hu unknown
- 2014-11-14 WO PCT/KR2014/010972 patent/WO2015072784A1/en active Application Filing
- 2014-11-14 AU AU2014349328A patent/AU2014349328A1/en not_active Abandoned
- 2014-11-14 CN CN201480060553.4A patent/CN105705150B/zh active Active
- 2014-11-14 KR KR1020167015696A patent/KR101869940B1/ko active IP Right Grant
- 2014-11-14 CA CA2926909A patent/CA2926909A1/en active Pending
- 2014-11-14 US US15/029,852 patent/US10500224B2/en active Active
- 2014-11-14 MX MX2016005900A patent/MX2016005900A/es unknown
- 2014-11-14 ES ES14862419T patent/ES2778524T3/es active Active
- 2014-11-14 EP EP14862419.0A patent/EP3068406B1/en active Active
- 2014-11-14 PL PL14862419T patent/PL3068406T3/pl unknown
- 2014-11-14 JP JP2016554157A patent/JP6215484B2/ja active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130196941A1 (en) * | 2010-07-13 | 2013-08-01 | Clavis Pharma Asa | Parenteral formulations of elacytarabine derivatives |
Non-Patent Citations (3)
Title |
---|
Evaluation of α-pyrones and pyrimidones as photoaffinity probes for affinity-based protein profiling;oliver A.等;《Journal of Organic Chemistry》;20110805;第76卷(第15期);表4的化合物16和26 * |
Nucleic acids. 11. Synthesis of 5"-esters of 1-beta-D-arabinofuranosylcytosine possessing antileukemic and immunosuppressive activity;DUANE T.等;《Journal of Medicinal Chemistry》;19711201;第14卷(第12期);第1159页表1 * |
oliver A.等.Evaluation of α-pyrones and pyrimidones as photoaffinity probes for affinity-based protein profiling.《Journal of Organic Chemistry》.2011,第76卷(第15期),表4的化合物16和26. * |
Also Published As
Publication number | Publication date |
---|---|
EP3068406A4 (en) | 2017-04-12 |
CN105705150A (zh) | 2016-06-22 |
CA2926909A1 (en) | 2015-05-21 |
WO2015072784A1 (en) | 2015-05-21 |
EP3068406B1 (en) | 2020-01-08 |
ES2778524T3 (es) | 2020-08-10 |
JP6215484B2 (ja) | 2017-10-18 |
DK3068406T3 (da) | 2020-03-30 |
PL3068406T3 (pl) | 2020-08-10 |
JP2016540829A (ja) | 2016-12-28 |
BR112016008934A2 (zh) | 2017-08-01 |
US20160228562A1 (en) | 2016-08-11 |
KR20160079886A (ko) | 2016-07-06 |
EP3068406A1 (en) | 2016-09-21 |
BR112016008934B1 (pt) | 2022-11-08 |
US10500224B2 (en) | 2019-12-10 |
KR101869940B1 (ko) | 2018-06-21 |
MX2016005900A (es) | 2016-07-13 |
HUE048844T2 (hu) | 2020-12-28 |
AU2014349328A1 (en) | 2016-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2644990T3 (es) | Síntesis estereoselectiva de principios activos que contienen fósforo | |
US8759318B2 (en) | Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections | |
CN107073005B (zh) | 治疗丝状病毒科病毒感染的方法 | |
EP2890704B1 (en) | 2'-ethynyl nucleoside derivatives for treatment of viral infections | |
EP2928877B1 (en) | Disulfide masked prodrug compositions and methods | |
CN107427530B (zh) | 用于HCV治疗的β-D-2’-脱氧-2’α-氟-2’-β-C-取代的-2-改性的-N6-取代的嘌呤核苷酸 | |
JP2005515196A (ja) | 3−β−D−リボフラノシルチアゾロ[4,5−d]ピリジミンヌクレオシド及びその使用 | |
KR20100102092A (ko) | 아자시티딘 유사체 및 이들의 용도 | |
CN105705150B (zh) | 用于癌症治疗的包含短链脂肪酸和折布拉林或1′-氰基-阿糖胞苷的互联体前药 | |
WO2015101183A1 (zh) | 尿嘧啶核苷酸类似物及其制备方法和应用 | |
EP3204121B1 (en) | Silylated 5-aza-pyrimidine prodrugs useful for treating cancer | |
KR102579485B1 (ko) | 5-아자사이티딘류의 당 부분(糖部) 실릴에테르 유도체 | |
US9828409B2 (en) | Bridged-cyclo-ProTides as prodrugs of therapeutic nucleosides and nucleotides | |
WO2020114495A1 (zh) | 二核苷酸化合物及其前体药物 | |
RU2731385C1 (ru) | Макрогетероциклические нуклеозидные производные и их аналоги, получение и применение | |
CN111918870B (zh) | 氘代的低聚核苷酸及前体药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160719 Address after: Gyeonggi Do City South Korea Bundang Panchiao road 712 branch No. 16 Prince Pasteur Institute Korea 4 floor Applicant after: Konka Nuo Medical Technology Development Co.,Ltd. Applicant after: YANGZHOU AIDEA BIOTECH Co.,Ltd. Applicant after: NANJING ANSAILAI MEDICAL SCIENCE & TECHNOLOGY Co.,Ltd. Address before: Gyeonggi Do City South Korea Bundang Panchiao road 712 branch No. 16 Prince Pasteur Institute Korea 4 floor Applicant before: Konka Nuo Medical Technology Development Co.,Ltd. |
|
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: Gyeonggi Do City South Korea Bundang Panchiao road 712 branch No. 16 Prince Pasteur Institute Korea 4 floor Applicant after: Konka Nuo Medical Technology Development Co.,Ltd. Applicant after: Jiangsu Aidi Pharmaceutical Co.,Ltd. Applicant after: NANJING ANSAILAI MEDICAL SCIENCE & TECHNOLOGY Co.,Ltd. Address before: Gyeonggi Do City South Korea Bundang Panchiao road 712 branch No. 16 Prince Pasteur Institute Korea 4 floor Applicant before: Konka Nuo Medical Technology Development Co.,Ltd. Applicant before: JIANGSU AIDEA PHARMACEUTICAL CO.,LTD. Applicant before: NANJING ANSAILAI MEDICAL SCIENCE & TECHNOLOGY Co.,Ltd. Address after: Gyeonggi Do City South Korea Bundang Panchiao road 712 branch No. 16 Prince Pasteur Institute Korea 4 floor Applicant after: Konka Nuo Medical Technology Development Co.,Ltd. Applicant after: JIANGSU AIDEA PHARMACEUTICAL CO.,LTD. Applicant after: NANJING ANSAILAI MEDICAL SCIENCE & TECHNOLOGY Co.,Ltd. Address before: Gyeonggi Do City South Korea Bundang Panchiao road 712 branch No. 16 Prince Pasteur Institute Korea 4 floor Applicant before: Konka Nuo Medical Technology Development Co.,Ltd. Applicant before: YANGZHOU AIDEA BIOTECH Co.,Ltd. Applicant before: NANJING ANSAILAI MEDICAL SCIENCE & TECHNOLOGY Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |